Dr. Shea is a renowned clinician who specializes in hematologic malignancies and bone marrow transplantation. He has served on the Executive Committee of the North American and International Bone Marrow Transplant Registry and is the current President of the Scientific Advisory Board of the Center for International Bone Marrow Transplant Research (CIBMTR), the world's largest repository of data on bone marrow and blood stem cell transplant outcomes.
Dr. Shea’s commitment to clinical research is evident in his leadership and involvement in clinical trials. He is a co-author in a recent publication in the New England Journal of Medicine that demonstrated that the drug lenalidomide used as maintenance therapy after bone marrow transplantation slows down the progression of multiple myeloma. These exciting results will change the treatment for multiple myeloma patients.
Dr. Shea is also the Associate Director for Outreach Programs for the UNC Lineberger Comprehensive Cancer Center, a program aimed at helping patients in communities located far away from major medical centers and who do not have frequent access to medical specialists.
Industry Expertise (3)
Areas of Expertise (4)
Bone Marrow Transplantation
Stem Cell Research
Harvard University: Fellowship, Hematology/Oncology 1985
University of North Carolina: Internship, Internal Medicine 1980
University of North Carolina at Chapel Hill: M.D., Medicine 1978
Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaThe New England Journal of Medicine
2012 BACKGROUND: Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma...
The Effects of an Exercise Program in Leukemia PatientsIntegrative Cancer Therapies
2010 To examine the feasibility of administering an in-hospital exercise program to acute leukemia patients undergoing chemotherapy. A secondary purpose explored the impact of exercise on selected physiological, psychological, and inflammatory markers. Methods. Ten patients, aged 18 to 50 years, diagnosed with acute leukemia or newly relapsed were assessed for body weight, height, body composition (skinfolds), cardiorespiratory endurance (total minutes on bicycle ergometer at 60% heart rate reserve), dynamic muscular endurance (Rocky Mountain Cancer Rehabilitation Institute protocol), fatigue (Revised Piper Fatigue Scale), depression (Center for Epidemiologic Studies Depression scale, National Institute of Mental Health questionnaire), and quality of life (Functional Assessment of Cancer Therapy—General) at baseline (within 3 days of diagnosis) and at the end of induction phase of treatment. Blood draws were taken at baseline, midpoint, and at the end of induction for analyses of inflammatory markers (Linco Luminex assay). Combined aerobic and strength training exercises were administered 3 times per week, twice daily, for 30 minutes. Paired-samples t-tests were used for the analyses of physiological and psychological parameters.
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyBlood
2002 Blast crisis is the most advanced stage of chronic myelogenous leukemia (CML) and is highly refractory to therapy. CML is caused by expression of the chimeric BCR-ABL tyrosine kinase oncogene, the product of the t(9;22) Philadelphia translocation. Imatinib (Glivec, formerly STI571) is a rationally developed, orally administered inhibitor of the Bcr-Abl tyrosine kinase. A total of 260 patients with CML were enrolled in a phase II trial, of whom 229 had a confirmed diagnosis of CML in blast crisis. Patients were treated with imatinib in daily oral doses of 400 mg or 600 mg...
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignanciesJournal of Clinical Oncology
2002 PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacodynamics (PD) of the proteasome inhibitor bortezomib (previously known as PS-341) in patients with refractory hematologic malignancies...
A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantationThe New England Journal of Medicine
1992 BACKGROUND AND METHODS: Superficial and systemic fungal infections are a major problem among severely immunocompromised patients who undergo bone marrow transplantation. We performed a double-blind, randomized , multicenter trial in which patients receiving bone marrow transplants were randomly assigned to receive placebo or fluconazole...